Next 10 |
home / stock / gild / gild articles
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.77% on an annualized basis producing an average annual return...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
Bank of America Securities downgrades European drugmaker Galapagos NV (NASDAQ:GLPG) to underperform, citing few catalysts in the near term. Gal...
Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer treat...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 4.71% on an annualized basis producing an average annual return...
Morgan Stanley initiates Arcellx Inc (NASDAQ:ACLX), noting a differentiated CAR-T platform for blood cancer backed by an established...
Gilead Sciences Inc (NASDAQ:GILD) and Merck & Co Inc (NYSE:MRK) released results from the Phase 2 clinical study evaluating the ...
Biogen Inc (NASDAQ:BIIB) released interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study. The Ph...
The Biden administration is working to preserve a crucial federal mandate compelling health insurers to cover preventive care services, including ...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report , which uses the ESG framework to highlight the successes and achievements of the prior year. In this year's report, you will see examples of Gilead's imp...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.77% on an annualized basis producing an average annual return...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...